Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 31-Jan-23 2:21 PM View:  | Sazdanoff Catherine Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 16,424 | -- | -- | (100%) 16.42K to 0 | |
| 31-Jan-23 2:15 PM View: | Anderson James M. Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 5,000 | -- | -- | (100%) 5.0K to 0 | |
| 31-Jan-23 2:08 PM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 25,600 | -- | -- | (100%) 25.6K to 0 | |
| 31-Jan-23 2:10 PM View: | Weltzien Lourdes Executive VP, Life Science | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 86,045 | -- | -- | (100%) 86.05K to 0 | |
| 31-Jan-23 2:12 PM View: | Kenny John P. Chief Executive Officer Director 10% Owner | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Grant | 47,060 | -- | -- | 21% 220.59K to 267.65K | |
| 31-Jan-23 2:20 PM View: | Rice John McCune Jr. Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 27,449 | -- | -- | (100%) 27.45K to 0 | |
| 31-Jan-23 2:09 PM View: | Serafini-Lamanna Tony Executive VP-Diagnostics | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 43,338 | -- | -- | (100%) 43.34K to 0 | |
| 31-Jan-23 2:16 PM View: | Bihl Anthony P III Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 15,408 | -- | -- | (100%) 15.41K to 0 | |
| 31-Jan-23 2:08 PM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Grant | 2,648 | -- | -- | 5% 55.66K to 58.31K | |
| 31-Jan-23 2:11 PM View: | Kitzmiller Andrew S. Executive Vice President & CFO | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Grant | 7,945 | -- | -- | 69% 11.53K to 19.47K | |
| 31-Jan-23 2:12 PM View: | Kenny John P. Chief Executive Officer Director 10% Owner | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 267,651 | -- | -- | (100%) 267.65K to 0 | |
| 31-Jan-23 2:22 PM View: | Williams Felicia Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 10,274 | -- | -- | (100%) 10.27K to 0 | |
| 31-Jan-23 2:15 PM View: | Anderson James M. Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 28,224 | -- | -- | (85%) 33.22K to 5.0K | |
| 31-Jan-23 2:08 PM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 32,708 | -- | -- | (56%) 58.31K to 25.6K | |
| 31-Jan-23 2:17 PM View: | Ellingwood Dwight E Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 17,290 | -- | -- | (100%) 17.29K to 0 | |
| 31-Jan-23 2:19 PM View: | McIlwraith John Director | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 21,724 | -- | -- | (100%) 21.72K to 0 | |
| 31-Jan-23 2:10 PM View: | Weltzien Lourdes Executive VP, Life Science | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Grant | 7,945 | -- | -- | 10% 78.1K to 86.05K | |
| 31-Jan-23 2:11 PM View: | Kitzmiller Andrew S. Executive Vice President & CFO | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Disposition | 19,473 | -- | -- | (100%) 19.47K to 0 | |
| 31-Jan-23 2:09 PM View: | Serafini-Lamanna Tony Executive VP-Diagnostics | Meridian Bioscience Inc. (VIVO) | 31-Jan-23 | Grant | 7,945 | -- | -- | 22% 35.39K to 43.34K | |
| 09-Jan-23 10:48 AM View: | Anderson James M. Director | Meridian Bioscience Inc. (VIVO) | 06-Jan-23 | Option Exercise | 8,500 | $20.38 | $173,230.00 | 34% 24.72K to 33.22K | 4% |
| 07-Dec-22 9:58 AM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 06-Dec-22 | Payment of Exercise | 374 | $31.71 | $11,859.50 | (< 1%) 56.03K to 55.66K | |
| 17-Nov-22 9:59 AM View: | Weltzien Lourdes EVP, Life Science | Meridian Bioscience Inc. (VIVO) | 15-Nov-22 | Payment of Exercise | 4,382 | $31.83 | $139,479.00 | (5%) 82.48K to 78.1K | |
| 17-Nov-22 10:05 AM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 15-Nov-22 | Payment of Exercise | 1,845 | $31.83 | $58,726.40 | (3%) 57.88K to 56.03K | |
| 17-Nov-22 10:03 AM View: | Serafini-Lamanna Tony Executive VP-Diagnostics | Meridian Bioscience Inc. (VIVO) | 15-Nov-22 | Payment of Exercise | 3,666 | $31.83 | $116,689.00 | (9%) 39.06K to 35.39K | |
| 08-Nov-22 2:32 PM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 04-Nov-22 | Payment of Exercise | 397 | $32.01 | $12,708.00 | (< 1%) 58.28K to 57.88K | |
| 08-Nov-22 2:29 PM View: | Serafini-Lamanna Tony Executive VP-Diagnostics | Meridian Bioscience Inc. (VIVO) | 04-Nov-22 | Payment of Exercise | 788 | $32.01 | $25,223.90 | (2%) 39.85K to 39.06K | |
| 08-Nov-22 2:25 PM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 04-Nov-22 | Payment of Exercise | 4,271 | $32.01 | $136,715.00 | (2%) 224.86K to 220.59K | |
| 08-Nov-22 2:31 PM View: | Weltzien Lourdes EVP, Life Science | Meridian Bioscience Inc. (VIVO) | 04-Nov-22 | Payment of Exercise | 566 | $32.01 | $18,117.70 | (< 1%) 83.05K to 82.48K | |
| 05-Oct-22 3:54 PM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 03-Oct-22 | Payment of Exercise | 40,269 | $31.53 | $1,269,680.00 | (15%) 265.13K to 224.86K | |
| 05-Oct-22 4:01 PM View: | Smith Julie Diana Sr VP, Controller, PAO | Meridian Bioscience Inc. (VIVO) | 16-Sep-22 | Payment of Exercise | 360 | $32.14 | $11,570.40 | (< 1%) 58.64K to 58.28K | |
| 05-Oct-22 3:58 PM View: | Serafini-Lamanna Tony Executive VP-Diagnostics | Meridian Bioscience Inc. (VIVO) | 16-Sep-22 | Payment of Exercise | 357 | $32.14 | $11,474.00 | (< 1%) 40.2K to 39.85K | |
| 28-Jun-22 9:42 AM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 27-Jun-22 | Option Exercise | 61,437 | $10.10 | $620,514.00 | 23% 265.13K to 326.57K | |
| 28-Jun-22 9:42 AM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 27-Jun-22 | Planned Option Sale | 61,437 | $30.39 | $1,866,790.00 | (19%) 326.57K to 265.13K | |
| 28-Jun-22 9:42 AM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 24-Jun-22 | Option Exercise | 13,559 | $10.10 | $136,946.00 | 5% 265.13K to 278.69K | |
| 28-Jun-22 9:42 AM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 24-Jun-22 | Planned Option Sale | 13,559 | $30.00 | $406,836.00 | (5%) 278.69K to 265.13K | |
| 24-Jun-22 12:33 PM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 23-Jun-22 | Option Exercise | 19,956 | $11.28 | $225,091.00 | 8% 265.13K to 285.09K | |
| 24-Jun-22 12:33 PM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 23-Jun-22 | Planned Option Sale | 19,956 | $29.98 | $598,209.00 | (7%) 285.09K to 265.13K | |
| 24-Jun-22 12:33 PM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 22-Jun-22 | Option Exercise | 44,651 | $14.50 | $647,440.00 | 17% 265.13K to 309.78K | |
| 24-Jun-22 12:33 PM View: | Kenny John P. Chief Executive Officer Director | Meridian Bioscience Inc. (VIVO) | 22-Jun-22 | Planned Option Sale | 44,651 | $29.72 | $1,326,920.00 | (14%) 309.78K to 265.13K | |
| 28-Feb-22 2:40 PM View: | Kitzmiller Andrew S. EVP & CFO | Meridian Bioscience Inc. (VIVO) | 25-Feb-22 | Purchase | 4,028 | $24.87 | $100,166.00 | 54% 7.5K to 11.53K | |
| 22-Feb-22 2:07 PM View: | Kitzmiller Andrew S. Executive Vice President & CFO | Meridian Bioscience Inc. (VIVO) | 21-Feb-22 | Grant | 7,500 | -- | -- | 100% 0 to 7.5K | |
| 17-Feb-22 11:22 AM View: | Weltzien Lourdes EVP, Life Science | Meridian Bioscience Inc. (VIVO) | 15-Feb-22 | Option Exercise | 20,000 | $14.52 | $290,375.00 | 24% 83.05K to 103.05K | |
| 17-Feb-22 11:22 AM View: | Weltzien Lourdes EVP, Life Science | Meridian Bioscience Inc. (VIVO) | 15-Feb-22 | Option Sale | 20,000 | $25.60 | $511,912.00 | (19%) 103.05K to 83.05K | |
| 28-Jan-22 11:41 AM View: | Rice John McCune Jr. Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 12% 24.44K to 27.45K | |
| 28-Jan-22 11:43 AM View: | Sazdanoff Catherine Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 22% 13.41K to 16.42K | |
| 28-Jan-22 11:32 AM View: | Anderson James M. Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 14% 21.71K to 24.72K | |
| 28-Jan-22 11:37 AM View: | McIlwraith John Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 16% 18.71K to 21.72K | |
| 28-Jan-22 11:36 AM View: | Ellingwood Dwight E Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 21% 14.28K to 17.29K | |
| 28-Jan-22 11:34 AM View: | Bihl Anthony P III Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 24% 12.4K to 15.41K | |
| 28-Jan-22 11:47 AM View: | Williams Felicia Director | Meridian Bioscience Inc. (VIVO) | 26-Jan-22 | Grant | 3,012 | -- | -- | 41% 7.26K to 10.27K |
